Skip to main content
. Author manuscript; available in PMC: 2021 Oct 12.
Published in final edited form as: Semin Immunol. 2017 Jun 2;29:14–23. doi: 10.1016/j.smim.2017.05.002

Fig. 4.

Fig. 4.

UBM promotes an M2-macrophage phenotype that matures over time. (a) CD206 and CD86 expression on 3 myeloid subtypes detected in the implant at 3 weeks post-injection. (b) CD86 expression quantified as mean fluorescence intensity (MFI) at 1 and 3 weeks post-injection. (c) CD206 expression quantified as MFI. Data are means ± SEM, n = 4 mice per group.